NASDAQ:CODX), and in this article, we analyze the executive’s compensation package with respect to the overall performance of the company. This analysis will also assess whether Co-Diagnostics pays its CEO appropriately, considering recent earnings growth and total shareholder returns.” data-reactid=”28″>Dwight Egan is the CEO of Co-Diagnostics, Inc. (NASDAQ:CODX), and in this article, we analyze the executive’s compensation package with respect to the overall performance of the company. This analysis will also assess whether Co-Diagnostics pays its CEO appropriately, considering recent earnings growth and total shareholder returns.
See our latest analysis for Co-Diagnostics ” data-reactid=”29″>See our latest analysis for Co-Diagnostics
How Does Total Compensation For Dwight Egan Compare With Other Companies In The Industry?
According to our data, Co-Diagnostics, Inc. has a market capitalization of US$442m, and paid its CEO total annual compensation worth US$460k over the year to December 2019. That’s mostly flat as compared to the prior year’s compensation. In particular, the salary of US$275.0k, makes up a huge portion of the total compensation being paid to the CEO.
In comparison with other companies in the industry with market capitalizations ranging from US$200m to US$800m, the reported median CEO total compensation was US$2.2m. Accordingly, Co-Diagnostics pays its CEO under the industry median.
| Component | 2019 | 2018 | Proportion (2019) |
| Salary | US$275k | US$275k | 60% |
| Other | US$185k | US$199k | 40% |
| Total Compensation | US$460k | US$474k | 100% |
On an industry level, roughly 21% of total compensation represents salary and 79% is other remuneration. Co-Diagnostics pays out 60% of remuneration in the form of a salary, significantly higher than the industry average. If total compensation veers towards salary, it suggests that the variable portion – which is generally tied to performance, is lower.
Co-Diagnostics, Inc.’s Growth
Co-Diagnostics, Inc.’s earnings per share (EPS) grew 34% per year over the last three years. Its revenue is up 29,885% over the last year.
this free visual report on analyst forecasts for the company’s future earnings..” data-reactid=”54″>This demonstrates that the company has been improving recently and is good news for the shareholders. Most shareholders would be pleased to see strong revenue growth combined with EPS growth. This combo suggests a fast growing business. Looking ahead, you might want to check this free visual report on analyst forecasts for the company’s future earnings..
Has Co-Diagnostics, Inc. Been A Good Investment?
Most shareholders would probably be pleased with Co-Diagnostics, Inc. for providing a total return of 216% over three years. This strong performance might mean some shareholders don’t mind if the CEO were to be paid more than is normal for a company of its size.
To Conclude…
As previously discussed, Dwight is compensated less than what is normal for CEOs of companies of similar size, and which belong to the same industry. Since EPS growth is heading in a positive direction; many would agree with our assessment that the pay is modest. Given the strong history of shareholder returns, the shareholders are probably very happy with Dwight’s performance.
4 warning signs for Co-Diagnostics (of which 2 are a bit unpleasant!) that you should know about in order to have a holistic understanding of the stock.” data-reactid=”59″>CEO compensation is an important area to keep your eyes on, but we’ve also need to pay attention to other attributes of the company. That’s why we did our research, and identified 4 warning signs for Co-Diagnostics (of which 2 are a bit unpleasant!) that you should know about in order to have a holistic understanding of the stock.
list of high return, low debt companies is a great place to look.” data-reactid=”60″>Switching gears from Co-Diagnostics, if you’re hunting for a pristine balance sheet and premium returns, this free list of high return, low debt companies is a great place to look.
Get in touch with us directly. Alternatively, email [email protected].” data-reactid=”61″>This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected].
